REPL insider transaction filings
Replimune Group, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-19. Screen REPL transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-19 | 4 | Hill Emily Luisa — Chief Financial Officer | Sale (S): 9,256 @ $14.28 | EDGAR |
| 2026-08-12 | 4 | Xynos Konstantinos — Chief Medical Officer | Sale (S): 11,447 @ $12.97 | EDGAR |
| 2026-08-12 | 4 | Hill Emily Luisa — Chief Financial Officer | Sale (S): 11,448 @ $12.97 | EDGAR |
| 2026-08-12 | 4 | Patel Sushil — Chief Executive Officer, Director | Sale (S): 39,341 @ $12.97 | EDGAR |
| 2026-08-12 | 4 | Schwendenman Andrew — Chief Accounting Officer | Sale (S): 7,632 @ $12.97 | EDGAR |
| 2026-08-11 | 4 | BAKER BROS. ADVISORS LP — Director, 10% owner Baker Bros. Advisors (GP) LLC — Director, 10% owner 667, L.P. — Director, 10% owner Baker Brothers Life Sciences LP — Director, 10% owner BAKER FELIX — Director, 10% owner BAKER JULIAN — Director, 10% owner | Purchase (P): 126,394 (derivative) @ $12.06 · Purchase (P): 2,609,946 (derivative) @ $12.06 | EDGAR |
| 2026-06-03 | 4 | Sarchi Christopher — Chief Commercial Officer | Sale (S): 12,000 @ $9.24 | EDGAR |
| 2026-05-20 | 4 | Xynos Konstantinos — Chief Medical Officer | Sale (S): 14,023 @ $5.08 | EDGAR |
| 2026-05-20 | 4 | Schwendenman Andrew — Chief Accounting Officer | Sale (S): 7,894 @ $5.08 | EDGAR |
| 2026-05-20 | 4 | Sarchi Christopher — Chief Commercial Officer | Sale (S): 8,626 @ $5.08 | EDGAR |
| 2026-05-20 | 4 | Patel Sushil — Chief Executive Officer, Director | Sale (S): 37,324 @ $5.08 | EDGAR |
| 2026-05-20 | 4 | Hill Emily Luisa — Chief Financial Officer | Sale (S): 7,812 @ $5.08 | EDGAR |
| 2026-05-20 | 4 | Astley-Sparke Philip — Director | Sale (S): 17,657 @ $5.08 | EDGAR |
| 2026-04-07 | 4 | Sarchi Christopher — Chief Commercial Officer | Grant/award (A): 50,000 @ $0 · Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-04-07 | 4 | Oliger Christy J. — Director | Grant/award (A): 44,500 (derivative) @ $0 | EDGAR |
| 2026-04-07 | 4 | Xynos Konstantinos — Chief Medical Officer | Grant/award (A): 50,000 @ $0 · Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-04-07 | 4 | Schwendenman Andrew — Chief Accounting Officer | Grant/award (A): 36,667 @ $0 · Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2026-04-07 | 4 | Patel Sushil — Chief Executive Officer, Director | Grant/award (A): 251,240 @ $0 · Grant/award (A): 376,860 (derivative) @ $0 | EDGAR |
| 2026-04-07 | 4 | Peeples-Dyer Veleka — Director | Grant/award (A): 44,500 (derivative) @ $0 | EDGAR |
| 2026-04-07 | 4 | Hill Emily Luisa — Chief Financial Officer | Grant/award (A): 50,000 @ $0 · Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-04-07 | 4 | Weinand Dieter — Director | Grant/award (A): 44,500 (derivative) @ $0 | EDGAR |
| 2026-04-07 | 4 | Balachandran Madhavan — Director | Grant/award (A): 44,500 (derivative) @ $0 | EDGAR |
| 2026-04-07 | 4 | Dhingra Kapil — Director | Grant/award (A): 44,500 (derivative) @ $0 | EDGAR |
| 2026-04-07 | 4 | Pucci Paolo — Director | Grant/award (A): 44,500 (derivative) @ $0 | EDGAR |
| 2026-04-07 | 4 | Astley-Sparke Philip — Director | Grant/award (A): 50,000 @ $0 · Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-04-07 | 4 | SLATTERY JOSEPH P — Director | Grant/award (A): 44,500 (derivative) @ $0 | EDGAR |
| 2026-04-07 | 4 | BAKER BROS. ADVISORS LP — Director, 10% owner Baker Bros. Advisors (GP) LLC — Director, 10% owner 667, L.P. — Director, 10% owner Baker Brothers Life Sciences LP — Director, 10% owner BAKER FELIX — Director, 10% owner BAKER JULIAN — Director, 10% owner | Grant/award (A): 44,500 (derivative) @ $0 · Grant/award (A): 44,500 (derivative) @ $0 | EDGAR |
| 2026-04-06 | 4 | Sarchi Christopher — Chief Commercial Officer | Sale (S): 6,500 @ $8.01 | EDGAR |
| 2026-02-20 | 4 | Astley-Sparke Philip — Director | Gift (G): 25,000 @ $0 | EDGAR |
| 2025-12-19 | 4 | Patel Sushil — Chief Executive Officer, Director | Grant/award (A): 200,000 @ $0 | EDGAR |
| 2025-12-19 | 4 | Xynos Konstantinos — Chief Medical Officer | Grant/award (A): 60,000 @ $0 | EDGAR |
| 2025-12-19 | 4 | Hill Emily Luisa — Chief Financial Officer | Grant/award (A): 60,000 @ $0 | EDGAR |
| 2025-12-19 | 4 | Sarchi Christopher — Chief Commercial Officer | Grant/award (A): 35,000 @ $0 | EDGAR |
| 2025-12-19 | 4 | Schwendenman Andrew — Chief Accounting Officer | Grant/award (A): 10,000 @ $0 | EDGAR |
| 2025-12-11 | 4 | Dhingra Kapil — Director | Option exercise (M): 3,169 @ $1.75 · Sale (S): 3,169 @ $10.40 · Option exercise (M): 3,169 (derivative) @ $0 | EDGAR |
| 2025-12-04 | 4 | Patel Sushil — Chief Executive Officer, Director | Sale (S): 10,000 @ $11.13 | EDGAR |
| 2025-11-19 | 4 | Sarchi Christopher — Chief Commercial Officer | Sale (S): 5,208 @ $9.10 | EDGAR |
| 2025-11-19 | 4 | Xynos Konstantinos — Chief Medical Officer | Sale (S): 7,248 @ $9.10 | EDGAR |
| 2025-08-19 | 4 | Hill Emily Luisa — Chief Financial Officer | Sale (S): 9,154 @ $5.37 | EDGAR |
| 2025-05-22 | 4 | Xynos Konstantinos — Chief Medical Officer | Sale (S): 7,952 @ $8.06 | EDGAR |
| 2025-05-22 | 4 | Schwendenman Andrew — Chief Accounting Officer | Sale (S): 3,287 @ $8.05 | EDGAR |
| 2025-05-22 | 4 | Patel Sushil — Chief Executive Officer, Director | Sale (S): 25,105 @ $8.06 | EDGAR |
| 2025-05-22 | 4 | Hill Emily Luisa — Chief Financial Officer | Sale (S): 2,535 @ $8.05 | EDGAR |
| 2025-05-22 | 4 | Sarchi Christopher — Chief Commercial Officer | Sale (S): 3,749 @ $8.05 | EDGAR |
| 2025-05-22 | 4 | Astley-Sparke Philip — Director | Sale (S): 32,279 @ $8.06 | EDGAR |
| 2025-04-03 | 4 | Peeples-Dyer Veleka — Director | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2025-04-03 | 4 | Patel Sushil — Chief Executive Officer, Director | Grant/award (A): 166,667 @ $0 · Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2025-04-03 | 4 | Xynos Konstantinos — Chief Medical Officer | Grant/award (A): 45,000 @ $0 · Grant/award (A): 67,500 (derivative) @ $0 | EDGAR |
| 2025-04-03 | 4 | Hill Emily Luisa — Chief Financial Officer | Grant/award (A): 45,000 @ $0 · Grant/award (A): 67,500 (derivative) @ $0 | EDGAR |
| 2025-04-03 | 4 | Weinand Dieter — Director | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Replimune Group, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-11 | 8-K/A | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-10 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-07 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-31 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-30 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-29 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-26 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-29 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-13 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=REPL returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →